Article Information
History
- March 6, 2022.
Article Versions
- Version 1 (October 7, 2021 - 09:47).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Abeer H. Obaid1,2,3,
- Chryssa Zografou1,2,
- Douangsone D. Vadysirisack4,
- Bailey Munro-Sheldon1,
- Miriam L. Fichtner1,2,
- Bhaskar Roy1,
- William M. Philbrick2,
- Jeffrey L. Bennett5,
- Richard J. Nowak1 and
- Kevin C. O’Connor1,2,*
- 1Department of Neurology, Yale School of Medicine, New Haven, CT 06511 USA
- 2Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511 USA
- 3Institute of Biomedical Studies, Baylor University, Waco, TX 76706 USA
- 4UCB Pharma, Cambridge, MA 02140, USA
- 5Departments of Neurology and Ophthalmology, Programs in Neuroscience and Immunology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, USA
- ↵*Corresponding Author:
Kevin C. O’Connor, PhD, Yale School of Medicine, 300 George Street Room 353J, New Haven, CT 06511, Ph: 203-737-3321; email: kevin.oconnor{at}yale.edu
Posted March 06, 2022.
Heterogeneity of acetylcholine receptor autoantibody-mediated complement activity in patients with myasthenia gravis
